Abstracts tagged "meta-analysis"

Abstract Number: 1593 • 2016 ACR/ARHP Annual Meeting
Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Natalia V. Zamora¹, Jean Tayar², Maria A. Lopez-Olivo³, Robin Christensen⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Gentic Internal Medicine-AT & EC, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁵Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Baricitinib is a small molecule inhibitor of the Janus kinase (JAK) pathways that reduce and modulate the production of inflammatory mediators and cytokines. We…
Abstract Number: 1780 • 2016 ACR/ARHP Annual Meeting
Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Jennifer Medlin¹, Karen Hansen², Sara McCoy³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Phenotypes often differ in late-onset systemic lupus erythematosus (SLE) compared to SLE features in early-onset patients. Prior studies have suggested that there may be…
Abstract Number: 1796 • 2016 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mario García-Carrasco^1,2, Pamela Soto-Santillan³, Samanda Adriana Rojas villarraga⁴, Nicolás Molano-González⁵ and Claudia Mendoza Pinto⁶, ¹Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico, ³Internal Medicine, Systemic Autoimmune Diseases Research Unit, IMSS, Puebla, México, Puebla, Mexico, ⁴Novartis de Colombia, Bogota, Colombia, ⁵Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogota, Colombia, ⁶Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico
Background/Purpose: Observational studies have indicated a high but heterogeneous prevalence of low bone mineral density (BMD) and vertebral fractures (FV) in patients with systemic lupus…
Abstract Number: 2939 • 2016 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Matthew J. Koster² and Kenneth J. Warrington³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-analysis Background/Purpose: Venous thromboembolism (VTE) is a common medical problem with a…
Abstract Number: 2945 • 2016 ACR/ARHP Annual Meeting
Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”
Ana Urruticoechea-Arana¹, Tatiana Cobo-Ibáñez², Virginia Villaverde García³, Montserrat Santos-Gómez⁴, Kelly Vargas Osorio⁵, Federico Díaz-González⁶, Leslie Fariñas Padrón⁵, Vanesa Calvo-Río⁷ and Ricardo Blanco Alonso⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain, ⁴Rheumatology, Hospital Can Misses, Ibiza, Spain, ⁵Family and Community Medicine, Hospital Can Misses, Ibiza, Spain, ⁶Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose:
Abstract Number: 610 • 2016 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials
Erin Murray¹, Yekaterina Butylkova¹, Alexandra Ellis¹, Martha Skup², Jasmina Kalabic³ and Vishvas Garg⁴, ¹Doctor Evidence, Santa Monica, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc, North Chicago, IL
Background/Purpose: Previously, several studies have meta-analyzed clinical, functional or structural efficacy of biologics in treating rheumatoid arthritis (RA) patients. However, the comparative efficacy of biologics…
Abstract Number: 38 • 2015 ACR/ARHP Annual Meeting
Impact of Obesity on the Disease Course of Rheumatoid Arthritis
Yang (Linda) Liu¹, Gilaad Kaplan², Bertus Eksteen³ and Cheryl Barnabe¹, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ³Division of Hepatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Obesity results in a higher risk for the development of rheumatoid arthritis (RA) but is associated with less radiographic damage. The evidence for the…
Abstract Number: 111 • 2015 ACR/ARHP Annual Meeting
The Mitochondrial DNA (mtDNA) Haplogroups Influence the Risk of Radiographic OA Progression. a Meta-Analysis
Angel Soto-Hermida¹, Ignacio Rego-Pérez¹, Juan Fernandez-Tajes¹, Mercedes Fernandez Moreno¹, Maria Eugenia Vazquez Mosquera¹, Estefanía Cortés-Pereira¹, Sara Relaño-Fernandez¹, Sonia Pertega², Natividad Oreiro¹, Carlos Fernandez-Lopez¹ and Francisco J. Blanco¹, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²Unidad de Epidemiología Clínica y Bioestadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain
Background/Purpose: In the last years the role played by the mtDNA haplogroups in the pathogenesis of OA attracted much attention. The aim of this study…
Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Xerxes Pundole¹, Maria A. Lopez-Olivo², Hira Cheema³, Gabriela Sanchez Petitto⁴, Maria E. Suarez-Almazor⁵ and Huifang Lu⁶, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Texas Tech Odessa, Odessa, TX, ⁴The University of Texas, Health Science Center, Houston, TX, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
Abstract Number: 439 • 2015 ACR/ARHP Annual Meeting
Progression of Radiographic Joint Destruction in Patients with Rheumatoid Arthritis Treated with a Biologic Agent in Combination with Methotrexate Versus a Biologic Alone: A Systematic Review and Meta-Analysis of Randomized Trials
Tanja Schjødt Jørgensen¹, Simon Tarp¹, Daniel E. Furst², Anna Døssing¹, Peter C. Taylor³, Henning Bliddal¹ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom
Background/Purpose : One of the frequently claimed advantages of biologic agents is their potential to arrest radiographic progression. The ability of disease-modifying antirheumatic drugs (DMARDs;…
Abstract Number: 835 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis to Determine If the Prevalence of Scleroderma Renal Crisis Decreasing with Time
Matthew Turk¹ and Janet E. Pope², ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease with increased mortality from various internal organ involvement. Scleroderma renal crisis (SRC) usually occurs…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 1389 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis of the Prevalence of the Ocular Manifestations in All Inflammatory Rheumatic Diseases
Jacqueline Hayworth¹ and Janet E. Pope², ¹Medicine, University of Western Ontario and U of Toronto, Toronto, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Many inflammatory rheumatic diseases (IRD) are associated with ocular involvement. The prevalence of these complications is not fully known. This meta-analysis was performed to…
Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting
Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea
Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Maeve Gamble¹ and Janet E. Pope², ¹Medicine, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].